Array BioPharma Inc (ARRY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH81714D
- Pages: 77
- November 2018
- Total Views:1144
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Array BioPharma Inc (Array) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of targeted small-molecule drugs indicated for the treatment of cancer and inflammatory diseases. The company's most advanced wholly-owned clinical stage drugs include binimetinib, a MEK inhibitor for cancer; encorafenib, a BRAF inhibitor for cancer; selumetinib, MEK inhibitor for various cancers and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy, (LMNA-DCM). It has several partner programs in collaborations with AstraZeneca; Roche Holding; Aslan Pharmaceuticals; Genentech; VentiRx Pharmaceuticals; Eli Lilly; Cascadian Therapeutics; and Loxo Oncology. Array is headquartered in Boulder, Colorado, the US.
Array BioPharma Inc (ARRY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Venture Financing 15
Loxo Oncology Raises USD 10 Million In Venture Financing 15
Partnerships 16
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Licensing Agreements 25
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Equity Offering 32
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For USD 75 Million 38
Array BioPharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For USD 60 Million 41
Debt Offering 43
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For USD 132 Million 44
Asset Transactions 46
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc-Key Competitors 47
Array BioPharma Inc-Key Employees 48
Array BioPharma Inc-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Oct 30, 2018: Array BioPharma reports financial results for the first quarter of fiscal 2019 50
Aug 14, 2018: Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2018 52
May 09, 2018: Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 56
Feb 06, 2018: Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 59
Oct 31, 2017: Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018 61
Aug 09, 2017: Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 64
May 10, 2017: Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 68
Feb 09, 2017: Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017 70
Corporate Communications 74
Apr 27, 2017: Shalini Sharp Joins Array BioPharma Board of Directors 74
Legal and Regulatory 75
Nov 21, 2017: Array Biopharma Lead Plaintiff Deadline Alert: Faruqi & Faruqi Encourages Investors Who Suffered Losses Exceeding USD 100,000 In Array Biopharma, Inc. To Contact The Firm 75
Product News 76
07/26/2018: Pierre Fabre Medicament receives CHMP's positive opinion for Braftovi 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
List Of Figure
List of Figures
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Array BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Loxo Oncology Raises USD 10 Million In Venture Financing 15
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For USD 75 Million 38
Array BioPharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For USD 60 Million 41
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For USD 132 Million 44
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc, Key Competitors 47
Array BioPharma Inc, Key Employees 48
Array BioPharma Inc, Other Locations 49
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Array BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Array BioPharma Inc (Array) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of targeted small-molecule drugs indicated for the treatment of cancer and inflammatory diseases. The company's most advanced wholly-owned clinical stage drugs include binimetinib, a MEK inhibitor for cancer; encorafenib, a BRAF inhibitor for cancer; selumetinib, MEK inhibitor for various cancers and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy, (LMNA-DCM). It has several partner programs in collaborations with AstraZeneca; Roche Holding; Aslan Pharmaceuticals; Genentech; VentiRx Pharmaceuticals; Eli Lilly; Cascadian Therapeutics; and Loxo Oncology. Array is headquartered in Boulder, Colorado, the US.
Array BioPharma Inc (ARRY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Venture Financing 15
Loxo Oncology Raises USD 10 Million In Venture Financing 15
Partnerships 16
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Licensing Agreements 25
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Equity Offering 32
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For USD 75 Million 38
Array BioPharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For USD 60 Million 41
Debt Offering 43
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For USD 132 Million 44
Asset Transactions 46
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc-Key Competitors 47
Array BioPharma Inc-Key Employees 48
Array BioPharma Inc-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Oct 30, 2018: Array BioPharma reports financial results for the first quarter of fiscal 2019 50
Aug 14, 2018: Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2018 52
May 09, 2018: Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 56
Feb 06, 2018: Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 59
Oct 31, 2017: Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018 61
Aug 09, 2017: Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 64
May 10, 2017: Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 68
Feb 09, 2017: Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017 70
Corporate Communications 74
Apr 27, 2017: Shalini Sharp Joins Array BioPharma Board of Directors 74
Legal and Regulatory 75
Nov 21, 2017: Array Biopharma Lead Plaintiff Deadline Alert: Faruqi & Faruqi Encourages Investors Who Suffered Losses Exceeding USD 100,000 In Array Biopharma, Inc. To Contact The Firm 75
Product News 76
07/26/2018: Pierre Fabre Medicament receives CHMP's positive opinion for Braftovi 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
List Of Figure
List of Figures
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Array BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Array BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Array BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Array BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Array BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Array BioPharma Acquires Encorafenib from Novartis Pharma 13
Loxo Oncology Raises USD 10 Million In Venture Financing 15
Array BioPharma Enters into Agreement with Pfizer 16
Amgen and Array BioPharma Enter into Agreement 17
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 18
Array BioPharma Enters into Agreement with Merck 19
Dana-Farber Cancer Institute Enters into Research Agreement with Array BioPharma 20
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 21
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 22
Array BioPharma Enters Into Drug Discovery Agreement With Global Blood Therapeutics 23
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 24
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 25
Ono Pharma Enters into Licensing Agreement with Array BioPharma 26
Mirati Therapeutics Exercises Option For Licensing Agreement With Array BioPharma 27
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 28
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 29
Loxo Oncology Amends Licensing Agreement With Array BioPharma 30
Array Biopharma Plans to Raise up to USD125 Million in Public Offering of Shares 32
Yarra Therapeutics Spins Out from Array BioPharma 33
Array BioPharma Raises USD258.7 Million in Public Offering of Shares 34
Array BioPharma Raises USD132.3 Million in Public Offering of Shares 36
Array Biopharma Announces Public Offering Of Shares For USD 75 Million 38
Array BioPharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 10 Million 39
Array BioPharma Completes Public Offering Of Common Stock For USD 60 Million 41
Array BioPharma Raises USD10 Million in Private Placement of 5% Notes Due 2017 43
Array BioPharma Completes Public Offering Of Notes Due 2020 For USD 132 Million 44
Accuratus Lab Services Acquires CMC Operation from Array BioPharma 46
Array BioPharma Inc, Key Competitors 47
Array BioPharma Inc, Key Employees 48
Array BioPharma Inc, Other Locations 49
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Array BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020